Quarterly report · Q3
9776.TEDINET S100SUF0
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥14.9bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥15.3bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥415m | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥817m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥418m | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥972m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥508m | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥891m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥312m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥493m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥305m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥578m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥16.9bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥16.9bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.8bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.1bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.8bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.0bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥93.67 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.72 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.85 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.53 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 64.0% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-12-31 | ¥92m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-12-31 | ¥90m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-12-31 | ¥66m |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥5.8bn |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥5.8bn |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥104m |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥8.3bn |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥8.3bn |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥548m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥722m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥477m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥7m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥15.2bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥14.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥477m |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥645m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥15.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥14.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥480m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥711m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥75m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥73m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | ¥49m |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥6.4bn |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥6.4bn |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥532m |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥601m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥726m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥495m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥8m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥15.7bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥15.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥495m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥15.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥15.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥498m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥1.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 389
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 85232000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | -7411000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 6411270000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 8039474000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 726418000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 15177162000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 72942000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 15250105000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 495312000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 495312000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2556000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 497868000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 6411270000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 8039474000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 1221730000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 15672474000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 75498000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 15747973000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 532200000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 600512000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | -7718000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 1124994000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 49123000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1174118000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 5769049000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 8272474000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 721661000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 14763186000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 89511000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 14852697000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 477046000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 477046000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2565000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 479611000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 5769049000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 8272474000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 1198708000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 15240233000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 92076000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 15332309000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 103667000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 548394000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | -6905000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 645156000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 65860000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 711017000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |